US firm 22nd Century expects to double its total annual revenue following the acquisition of GVB Biopharma – which it describes as one of the largest global CBD suppliers – as part of a plan to rapidly grow its hemp/cannabis business.

“We are actively pursuing additional contracts in the industry to accelerate GVB’s existing growth opportunities while working to integrate our high-yield plant strains into GVB’s supply chain, further enhancing the productivity and profitability of this franchise,” said James Mish, 22nd Century Group’s CEO.

Read full article
I'm already a subscriber

Antonia Di Lorenzo

Assistant news editor
Antonia is a member of the editorial team and holds a masters degree in Law from the University of Naples Federico II, Italy. She moved in 2013 to London, where she completed a postgraduate course at the London School of Journalism. In the UK, she worked as a news reporter for a financial newswire and a magazine before moving to Barcelona in 2019.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization